Baseline characteristics of the North American prodromal Synucleinopathy cohort.
Baseline characteristics of the North American prodromal Synucleinopathy cohort.
复制标题
DOI：
10.1002/acn3.51738
复制
发表时间：
2023-04
影响因子：
5.3
通讯作者：
Ju, Yo-El S.
中科院分区：
文献类型：
--
作者：
Elliott, Jonathan E.;Lim, Miranda M.;Keil, Allison T.;Postuma, Ronald B.;Pelletier, Amelie;Gagnon, Jean-Francois;St Louis, Erik K.;Forsberg, Leah K.;Fields, Julie A.;Huddleston, Daniel E.;Bliwise, Donald L.;Avidan, Alon Y.;Howell, Michael J.;Schenck, Carlos H.;McLeland, Jennifer;Criswell, Susan R.;Videnovic, Aleksandar;During, Emmanuel H.;Miglis, Mitchell G.;Shprecher, David R.;Lee-Iannotti, Joyce K.;Boeve, Bradley F.;Ju, Yo-El S.
快速眼动（REM）睡眠行为障碍（RBD）被广泛认为是一种前驱性突触核蛋白病，因为大多数RBD患者在约10年内会发展为明显的突触核蛋白病。因此，RBD为在突触核蛋白病的最早阶段测试潜在治疗方法提供了机会。北美前驱性突触核蛋白病（NAPS）联盟创建了一个多中心的RBD参与者队列，主要基于临床，以更好地了解诊断时的特征，并在未来的工作中确定表型转化的预测因子，开发突触核蛋白病生物标志物，并使早期临床试验能够招募参与者。
年龄≥18岁、经整夜多导睡眠图确诊为RBD且无帕金森病、痴呆、多系统萎缩或发作性睡病的患者从北美9个地点入组（2018年8月至2021年4月）。数据收集包括RBD的家族/个人病史以及对认知、运动、感觉和自主神经功能的标准化评估。
结果主要根据性别报告（共361人：男性n = 295，女性n = 66），其次根据抗抑郁药使用史（使用n = 200，未使用n = 154；对性别差异进行校正）以及根据突触核蛋白病负担程度（n = 56定义为孤立性RBD，n = 305定义为RBD +[即表现出≥1种异常]）报告。总体而言，这些参与者普遍在整体认知（蒙特利尔认知评估量表；38%）、运动功能（交替敲击试验；48%）、感觉（身体两侧同时刺激试验；57%）、自主神经功能（直立性低血压，38.8%）以及焦虑/抑郁（贝克焦虑量表和患者健康问卷 - 9；分别为39.3%和31%）方面表现出异常。
这些RBD参与者经过广泛的病史、人口统计学、认知、运动、感觉和自主神经功能评估，显示出无性别差异以及伴随神经异常的高频率。这些参与者对于未来的纵向研究和神经保护临床试验将是有价值的。
Rapid eye movement (REM) sleep behavior disorder (RBD) is widely considered a prodromal synucleinopathy, as most with RBD develop overt synucleinopathy within ~10 years. Accordingly, RBD offers an opportunity to test potential treatments at the earliest stages of synucleinopathy. The North American Prodromal Synucleinopathy (NAPS) Consortium has created a multisite RBD participant, primarily clinic‐based cohort to better understand characteristics at diagnosis, and in future work, identify predictors of phenoconversion, develop synucleinopathy biomarkers, and enable early stage clinical trial enrollment. Participants ≥18 years of age with overnight polysomnogram‐confirmed RBD without Parkinson's disease, dementia, multiple system atrophy, or narcolepsy were enrolled from nine sites across North America (8/2018 to 4/2021). Data collection included family/personal history of RBD and standardized assessments of cognitive, motor, sensory, and autonomic function. Outcomes are primarily reported based on sex (361 total: n = 295 male, n = 66 female), and secondarily based on history of antidepressant use (n = 200 with, n = 154 without; with correction for sex differences) and based on extent of synucleinopathy burden (n = 56 defined as isolated RBD, n = 305 defined as RBD+ [i.e., exhibiting ≥1 abnormality]). Overall, these participants commonly demonstrated abnormalities in global cognition (MoCA; 38%), motor function (alternate tap test; 48%), sensory (BSIT; 57%), autonomic function (orthostatic hypotension, 38.8%), and anxiety/depression (BAI and PHQ‐9; 39.3% and 31%, respectively). These RBD participants, assessed with extensive history, demographic, cognitive, motor, sensory, and autonomic function demonstrated a lack of sex differences and high frequency of concomitant neurological abnormalities. These participants will be valuable for future longitudinal study and neuroprotective clinical trials.
登录
查看更多内容
影响因子：
3.7
作者：
Mamiya Y;Nishio Y;Watanabe H;Yokoi K;Uchiyama M;Baba T;Iizuka O;Kanno S;Kamimura N;Kazui H;Hashimoto M;Ikeda M;Takeshita C;Shimomura T;Mori E
通讯作者：
Mori E
影响因子：
4.8
作者：
Boeve, B. F.;Silber, M. H.;Ferman, T. J.;Lin, S. C.;Benarroch, E. E.;Schmeichel, A. M.;Ahlskog, J. E.;Caselli, R. J.;Jacobson, S.;Sabbagh, M.;Adler, C.;Woodruff, B.;Beach, T. G.;Iranzo, A.;Gelpi, E.;Santamaria, J.;Tolosa, E.;Singer, C.;Mash, D. C.;Luca, C.;Arnulf, I.;Duyckaerts, C.;Schenck, C. H.;Mahowald, M. W.;Dauvilliers, Y.;Graff-Radford, N. R.;Wszolek, Z. K.;Parisi, J. E.;Dugger, B.;Murray, M. E.;Dickson, D. W.
通讯作者：
Dickson, D. W.
影响因子：
3.5
作者：
Doty, RL;McKeown, DA;Shaman, P
通讯作者：
Shaman, P
影响因子：
4.8
作者：
Ju, Yo-El;Larson-Prior, Linda;Duntley, Stephen
通讯作者：
Duntley, Stephen
影响因子：
2.1
作者：
Besser L;Kukull W;Knopman DS;Chui H;Galasko D;Weintraub S;Jicha G;Carlsson C;Burns J;Quinn J;Sweet RA;Rascovsky K;Teylan M;Beekly D;Thomas G;Bollenbeck M;Monsell S;Mock C;Zhou XH;Thomas N;Robichaud E;Dean M;Hubbard J;Jacka M;Schwabe-Fry K;Wu J;Phelps C;Morris JC;Neuropsychology Work Group, Directors, and Clinical Core leaders of the National Institute on Aging-funded US Alzheimer’s Disease Centers
通讯作者：
Neuropsychology Work Group, Directors, and Clinical Core leaders of the National Institute on Aging-funded US Alzheimer’s Disease Centers